Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

Eric Hollander, William Chaplin, Latha Soorya, Stacey Wasserman, Sherry Novotny, Jade Rusoff, Nicole Feirsen, Lauren Pepa, Evdokia Anagnostou

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by social and language deficits and by repetitive behaviors and interests. Irritability/aggression is a significant comorbid symptom in this population, which greatly impacts burden of care. This study examined the effect of divalproex sodium for irritability/aggression in children and adolescents with ASD. This was a 12-week randomized, double-blind, placebo-controlled trial. All efficacy measures were obtained by an independent evaluator blinded to randomization condition and side effects. A total of 55 subjects gavetheir consent and 27 were randomized in a 1: 1 manner (mean age 9.462.46, mean nonverbal IQ 63.323.9). Two subjects from the active group and one subject from the placebo group discontinued the study because of either a lack of efficacy or side effects (increased irritability). Primary outcome measures were Aberrant Behavior Checklist-Irritability subscale and Clinical Global Impression-Improvement, which focused on irritability. Overall, 62.5% of divalproex subjects vs 9% of placebo subjects were responders (CGI-irritability OR: 16.7, Fisher's exact p0.008). A statistically significant improvement was also noted on the ABC-Irritability subscale (p0.048). There was a trend for responders to have higher valproate blood levels compared with nonresponders. This study suggests the efficacy of divalproex for the treatment of irritability in children and adolescents with ASD. Larger sample follow-up studies are warranted.

Original languageEnglish (US)
Pages (from-to)990-998
Number of pages9
JournalNeuropsychopharmacology
Volume35
Issue number4
DOIs
StatePublished - Mar 2010

Fingerprint

Valproic Acid
Placebos
Aggression
Therapeutics
Random Allocation
Checklist
Language
Outcome Assessment (Health Care)
Autism Spectrum Disorder
Population

Keywords

  • Adolescents
  • ASD
  • Children
  • Divalproex
  • Irritability

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. / Hollander, Eric; Chaplin, William; Soorya, Latha; Wasserman, Stacey; Novotny, Sherry; Rusoff, Jade; Feirsen, Nicole; Pepa, Lauren; Anagnostou, Evdokia.

In: Neuropsychopharmacology, Vol. 35, No. 4, 03.2010, p. 990-998.

Research output: Contribution to journalArticle

Hollander, E, Chaplin, W, Soorya, L, Wasserman, S, Novotny, S, Rusoff, J, Feirsen, N, Pepa, L & Anagnostou, E 2010, 'Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders', Neuropsychopharmacology, vol. 35, no. 4, pp. 990-998. https://doi.org/10.1038/npp.2009.202
Hollander, Eric ; Chaplin, William ; Soorya, Latha ; Wasserman, Stacey ; Novotny, Sherry ; Rusoff, Jade ; Feirsen, Nicole ; Pepa, Lauren ; Anagnostou, Evdokia. / Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. In: Neuropsychopharmacology. 2010 ; Vol. 35, No. 4. pp. 990-998.
@article{1388bb821af6478a941ea88a309e3478,
title = "Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders",
abstract = "Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by social and language deficits and by repetitive behaviors and interests. Irritability/aggression is a significant comorbid symptom in this population, which greatly impacts burden of care. This study examined the effect of divalproex sodium for irritability/aggression in children and adolescents with ASD. This was a 12-week randomized, double-blind, placebo-controlled trial. All efficacy measures were obtained by an independent evaluator blinded to randomization condition and side effects. A total of 55 subjects gavetheir consent and 27 were randomized in a 1: 1 manner (mean age 9.462.46, mean nonverbal IQ 63.323.9). Two subjects from the active group and one subject from the placebo group discontinued the study because of either a lack of efficacy or side effects (increased irritability). Primary outcome measures were Aberrant Behavior Checklist-Irritability subscale and Clinical Global Impression-Improvement, which focused on irritability. Overall, 62.5{\%} of divalproex subjects vs 9{\%} of placebo subjects were responders (CGI-irritability OR: 16.7, Fisher's exact p0.008). A statistically significant improvement was also noted on the ABC-Irritability subscale (p0.048). There was a trend for responders to have higher valproate blood levels compared with nonresponders. This study suggests the efficacy of divalproex for the treatment of irritability in children and adolescents with ASD. Larger sample follow-up studies are warranted.",
keywords = "Adolescents, ASD, Children, Divalproex, Irritability",
author = "Eric Hollander and William Chaplin and Latha Soorya and Stacey Wasserman and Sherry Novotny and Jade Rusoff and Nicole Feirsen and Lauren Pepa and Evdokia Anagnostou",
year = "2010",
month = "3",
doi = "10.1038/npp.2009.202",
language = "English (US)",
volume = "35",
pages = "990--998",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

AU - Hollander, Eric

AU - Chaplin, William

AU - Soorya, Latha

AU - Wasserman, Stacey

AU - Novotny, Sherry

AU - Rusoff, Jade

AU - Feirsen, Nicole

AU - Pepa, Lauren

AU - Anagnostou, Evdokia

PY - 2010/3

Y1 - 2010/3

N2 - Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by social and language deficits and by repetitive behaviors and interests. Irritability/aggression is a significant comorbid symptom in this population, which greatly impacts burden of care. This study examined the effect of divalproex sodium for irritability/aggression in children and adolescents with ASD. This was a 12-week randomized, double-blind, placebo-controlled trial. All efficacy measures were obtained by an independent evaluator blinded to randomization condition and side effects. A total of 55 subjects gavetheir consent and 27 were randomized in a 1: 1 manner (mean age 9.462.46, mean nonverbal IQ 63.323.9). Two subjects from the active group and one subject from the placebo group discontinued the study because of either a lack of efficacy or side effects (increased irritability). Primary outcome measures were Aberrant Behavior Checklist-Irritability subscale and Clinical Global Impression-Improvement, which focused on irritability. Overall, 62.5% of divalproex subjects vs 9% of placebo subjects were responders (CGI-irritability OR: 16.7, Fisher's exact p0.008). A statistically significant improvement was also noted on the ABC-Irritability subscale (p0.048). There was a trend for responders to have higher valproate blood levels compared with nonresponders. This study suggests the efficacy of divalproex for the treatment of irritability in children and adolescents with ASD. Larger sample follow-up studies are warranted.

AB - Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by social and language deficits and by repetitive behaviors and interests. Irritability/aggression is a significant comorbid symptom in this population, which greatly impacts burden of care. This study examined the effect of divalproex sodium for irritability/aggression in children and adolescents with ASD. This was a 12-week randomized, double-blind, placebo-controlled trial. All efficacy measures were obtained by an independent evaluator blinded to randomization condition and side effects. A total of 55 subjects gavetheir consent and 27 were randomized in a 1: 1 manner (mean age 9.462.46, mean nonverbal IQ 63.323.9). Two subjects from the active group and one subject from the placebo group discontinued the study because of either a lack of efficacy or side effects (increased irritability). Primary outcome measures were Aberrant Behavior Checklist-Irritability subscale and Clinical Global Impression-Improvement, which focused on irritability. Overall, 62.5% of divalproex subjects vs 9% of placebo subjects were responders (CGI-irritability OR: 16.7, Fisher's exact p0.008). A statistically significant improvement was also noted on the ABC-Irritability subscale (p0.048). There was a trend for responders to have higher valproate blood levels compared with nonresponders. This study suggests the efficacy of divalproex for the treatment of irritability in children and adolescents with ASD. Larger sample follow-up studies are warranted.

KW - Adolescents

KW - ASD

KW - Children

KW - Divalproex

KW - Irritability

UR - http://www.scopus.com/inward/record.url?scp=76749085678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749085678&partnerID=8YFLogxK

U2 - 10.1038/npp.2009.202

DO - 10.1038/npp.2009.202

M3 - Article

VL - 35

SP - 990

EP - 998

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 4

ER -